Methoxphenidine
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MXP (methoxphenidine) is a synthetic dissociative of the diarylethylamine class. It is a structural analog of diphenidine, distinguished by a longer duration and the absence of direct DAT activity.[1] MXP is an NMDA receptor antagonist, producing its effects by blocking glutamate signaling in cortical and subcortical circuits.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First described in a 1989 patent by G.D. Searle & Co. for the treatment of neurotoxic injury, methoxphenidine was never advanced to clinical trials.[3] It appeared on recreational markets in 2013 as a legal alternative to ketamine and methoxetamine following UK restrictions on arylcyclohexylamines.[4] MXP is now controlled in several countries including the UK, Canada, and France, though it was not added to the UN Convention on Psychotropic Substances.
Subjective effects include cognitive disconnection, derealization, spatial disorientation, and visual suppression. The experience is defined by its biphasic character — alternating waves of stimulant-like energy and heavy dissociative sedation rather than a smooth arc, with higher doses tilting decisively toward immobility.[4] Slow onset invites accidental redosing,[5] and unsought effects include anxiety, agitation, confusion, and seizures.
Physical dependence can develop after short periods of heavy use,[6] and 31 UK deaths have involved MXP alone or in combination.[7] Street samples may contain zinc halide impurities from synthesis that dramatically increase toxicity beyond what the compound itself would produce.[8] No controlled human study has been conducted — the entire evidence base rests on animal pharmacology, forensic case reports, and user accounts.
History[edit]
Discovery
Methoxphenidine was first described in a patent filed in 1989 by Nancy M. Gray and Brian K. Cheng of G.D. Searle & Co. (now Pfizer), covering the treatment of neurotoxic injury using 1,2-diarylethylamines.[9][3] The diarylethylamine backbone dates to the 1940s; the related compound lefetamine was investigated in Japan in the 1950s as an analgesic, and the structural class later produced clinical-stage NMDA antagonists lanicemine and remacemide before members began appearing as recreational drugs.[2][10]
Emergence and market trajectory
MXP appeared on research chemical markets in mid-to-late 2013, marketed explicitly as a legal alternative to methoxetamine and ketamine following UK scheduling actions against arylcyclohexylamines.[4][9] The first clinical toxicity case was published in 2014,[9] the first fatalities in 2015,[11] and the French Addictovigilance Network tracked increasing case numbers through a peak in 2016.[12]
Regulatory response
The UK Advisory Council on the Misuse of Drugs published its review of diarylethylamines in 2023, recommending Class B scheduling.[6] MXP became a Class B, Schedule 1 substance in the UK on 20 March 2024.[13] The WHO Expert Committee on Drug Dependence reviewed MXP in October 2020; the Commission on Narcotic Drugs decided in April 2021 not to add it to the UN Convention on Psychotropic Substances but placed it under continuing surveillance.[6]
The abbreviation MXP (sometimes 2-MXP or 2-MeO-diphenidine) reflects the compound's position as the 2-methoxy-substituted variant of diphenidine. The "2-" prefix distinguishes it from its positional isomers 3-MXP and 4-MXP, which carry different pharmacological profiles.[14] MXP's market identity was shaped entirely by regulatory displacement — it arrived not on its own merits but as a substitute for compounds that had been restricted, a pattern common among novel psychoactive substances.
Chemistry[edit]
Structural class
Methoxphenidine belongs to the 1,2-diarylethylamine structural family — compounds sharing a two-carbon chain bridging two aromatic rings with an amine substituent. It is a direct structural analog of diphenidine, differing by the addition of a methoxy (-OCH₃) group at the ortho position of one phenyl ring.[14][2]
The diarylethylamine class includes several other compounds that have appeared on novel psychoactive substance markets, including Diphenidine and ephenidine. Three positional isomers of methoxphenidine exist (2-, 3-, and 4-methoxydiphenidine), each with different pharmacological profiles; the 2-isomer is the most commonly encountered.[14]
Molecular properties
| Molecular formula | C₂₀H₂₅NO |
| Molecular weight | 295.4 g/mol |
The molecule consists of a piperidine ring linked via a methine carbon to a 2-methoxyphenyl ring and a benzyl group. The ortho-methoxy substituent is the key structural feature distinguishing MXP from the parent compound Diphenidine and from the 3- and 4-positional isomers.[14]
Stereochemistry
Methoxphenidine has one chirality center at the α-carbon, generating (R)- and (S)-enantiomers. The compound is sold and studied as the racemic mixture. In rats dosed with racemic MXP, the (S)-enantiomer accumulates to higher brain concentrations than the (R)-form, indicating enantioselective distribution into the central nervous system.[15] Whether this translates to differences in potency or effect profile has not been established.
Pharmacology[edit]
Mechanism of action
Methoxphenidine is a potent NMDA receptor antagonist. It blocks the ion channel of the NMDA in a use-dependent manner — preferentially binding open channels on active neurons — placing it in the same potency range as ketamine.[2][6]
MXP also binds moderately to the sigma-1 receptor, though whether this represents functional activation or blockade has not been determined.[6]inferred
A critical distinction from its parent compound diphenidine is MXP's negligible activity at monoamine transporters. Diphenidine directly increases dopamine release via the DAT; MXP does not.[1] MXP's SERT affinity is essentially absent, and NET affinity is very low.[2]
Despite the absence of direct dopamine transporter activity, MXP produces rewarding behaviors in rodents — self-administration and conditioned place preference — accompanied by dopamine release in reward circuits.[16] This occurs through an indirect mechanism: NMDA blockade releases inhibition on dopamine-producing neurons, rather than directly blocking dopamine reuptake.[1][16]
Pharmacokinetics
No human pharmacokinetic data exist for methoxphenidine. All parameters derive from rat studies.
In rats, MXP reaches peak blood and brain concentrations within approximately 30 minutes of administration, rapidly crosses the blood-brain barrier, and accumulates in brain tissue at concentrations roughly eight times higher than in blood.[17][15] The rat half-life is approximately 2 hours,[17] though this cannot be directly extrapolated to humans — the 6–8 hour reported human duration suggests substantially longer elimination or prolonged receptor binding in humans.
The primary metabolic pathway is removal of the methoxy group (O-demethylation), producing O-desmethyl-methoxphenidine.[15][11] This metabolite persists longer than the parent compound in brain tissue.[15] The (S)-enantiomer achieves higher brain concentrations than (R)-MXP following racemic mixture dosing, indicating the two mirror-image forms distribute differently into the brain.[15]
Human oral bioavailability, volume of distribution, protein binding, and elimination half-life are all unknown. Which liver enzymes metabolize MXP has not been identified, though structural analogy suggests involvement of common drug-metabolizing enzymes.inferred
Neuroscience[edit]
Where it acts
MXP's dissociative effects arise from NMDA blockade across cortical and subcortical brain networks. As a channel blocker that preferentially targets active neurons, MXP disproportionately silences inhibitory interneurons in the cortex — paradoxically increasing cortical excitation while disrupting the organized flow of information between brain regions.[2] This disruption of thalamocortical and cortico-cortical signaling is the neurophysiological basis of the dissociative state: the brain continues to generate activity, but the integration of that activity into coherent experience breaks down.
Why it matters
MXP's pharmacology illustrates a key principle of dissociative neuroscience: reward circuit activation without direct DAT involvement. MXP drives dopamine release in the nucleus accumbens and disrupts hippocampal–prefrontal communication in rodents,[16] entirely through NMDA-mediated disinhibition of dopamine neurons — not through direct reuptake blockade.[1] This indirect mechanism produces both the reinforcing properties that drive repeated use and the schizophrenia-like behavioral disruptions (hyperactivity, social withdrawal, cognitive impairment) observed in animal models.[16]
Several fundamental questions remain unanswered. The (S)-enantiomer accumulates preferentially in brain tissue,[15] but whether the two enantiomers differ in receptor binding, potency, or subjective character is unknown. Whether MXP triggers rapid neuroplasticity via mechanisms similar to ketamine has not been investigated.
Subjective Effects[edit]
The MXP experience is characterized by its unpredictable, wave-like quality. Rather than a smooth onset-peak-offset arc typical of most dissociatives, users describe alternating surges of stimulant-like energy and heavy dissociative sedation, with the balance shifting toward immobility and cognitive shutdown as dose increases.[4] A slow oral onset creates a deceptive window in which the full effects have not yet arrived, driving accidental redosing — a risk consistently flagged in community discourse.[5] Set, setting, and prior dissociative tolerance strongly modulate the character and intensity of the experience.
Compared to ketamine, MXP produces a longer, less controllable dissociative state with more stimulant character at lower doses and a slower, less predictable trajectory to peak effects. Compared to diphenidine, MXP is reported as less euphoric — consistent with its lack of direct DAT activity[1] — but longer-lasting and with a more gradual resolution.
Effect Grid
At common doses (75–120 mg oral), the full dissociative experience manifests. Cognitive disconnection deepens into pronounced derealization and depersonalization. Spatial disorientation becomes significant — navigation of physical space requires deliberate effort. Visual processing suppression is evident: double vision, reduced visual acuity, and flattened depth perception. Amnesia for portions of the experience is common. The biphasic stimulant-sedative wave pattern reported by users is most apparent at this range.
Physically, hypertension and tachycardia are expected based on clinical intoxication data. Body feels heavy or numb. Motor coordination is substantially impaired, and speech may become slurred or difficult.
Duration is 6–8 hours with 1–3 hours of aftereffects. Functional impairment persists well beyond the subjective peak. Planning for an extended time commitment is essential.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sensory deprivation · Touch suppression · Music enhancement · Visual acuity suppression · Depth perception distortion · Auditory distortion · Auditory suppression · Visual haze / noise · Dreaming enhancement · Tracers · Visual drifting · Tinnitus · Visual processing suppression · Internal hallucinations · External hallucinations · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations
Depth perception distortion · Auditory distortion · Auditory suppression · Visual haze / noise · Dreaming enhancement · Tracers · Visual drifting · Tinnitus · Visual processing suppression · Internal hallucinations · External hallucinations · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations
Sedation · Bodily lightness · Body high · Body schema distortion · Spontaneous body sensations · Bodily heaviness · Muscle relaxation · Pupil dilation · Tingling / electric sensations · Sexual arousal suppression · Heart rate perception changes · Laughter fits · Nausea · Tactile euphoria · Vibrations / buzzing · Stimulation · Motor control enhancement · Bodily dissociation
Spontaneous body sensations · Bodily heaviness · Muscle relaxation · Pupil dilation · Tingling / electric sensations · Sexual arousal suppression · Heart rate perception changes · Laughter fits · Nausea · Tactile euphoria · Vibrations / buzzing · Stimulation · Motor control enhancement · Bodily dissociation
Information processing suppression · Thought deceleration · Analysis suppression · Cognitive euphoria · Focus suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Cognitive fatigue · Humor enhancement · Conceptual thinking · Cognitive dysphoria · Compulsive redosing urge · Immersion enhancement · Introspection enhancement · Language suppression · Thought loops · Thought acceleration · Delusions of sobriety · Creativity enhancement · Amnesia · Delirium
Cognitive euphoria · Focus suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Cognitive fatigue · Humor enhancement · Conceptual thinking · Cognitive dysphoria · Immersion enhancement · Introspection enhancement · Language suppression · Thought loops · Thought acceleration · Delusions of sobriety · Creativity enhancement · Amnesia · Delirium
Emotional lability · Empathy suppression · Dysphoria
Sociability suppression · Social disconnection · Craving · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Boundary dissolution · Ego dissolution · Identity alteration
Timeline
First alerts emerge 30–60 minutes after ingestion: a subtle shift in spatial awareness, mild light-headedness, and faint cognitive slowing. The slow onset is a distinctive feature of oral MXP and a primary driver of accidental redosing.
Dissociative effects build steadily over 30–60 minutes. Spatial disorientation, visual dulling, and cognitive disconnection become progressively more apparent. A stimulant-like energy wave is common during this phase.
Maximum dissociative intensity sustained for 2–3 hours. Derealization, depersonalization, and visual processing suppression dominate. Motor coordination is significantly impaired.
Effects plateau at moderate intensity for 1. 5–2 hours. Dissociation remains present but the acute peak subsides.
Gradual return toward baseline over 1–1. 5 hours. Dissociative effects fade but residual spatial disorientation, cognitive fog, and mild derealization persist.
Residual effects lasting 1–3 hours: mild cognitive haze, emotional blunting or subtle mood elevation, and lingering fatigue. Some users report a sense of empowerment or clarity during this phase.
⚠ Do not drive or operate machinery until the following day, as residual dissociative impairment and slowed reaction times may persist beyond subjective awareness.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- dissociatives
Toxicity
Acute toxicity
No lethal dose or therapeutic index has been established in humans. The wide range of post-mortem blood concentrations in fatal cases (1.36–24.0 mg/L) makes it impossible to identify a reliable lethal threshold — individual variation and polydrug use confound the picture.[11]
Fatalities
Multiple deaths have been documented. The first reported fatalities (3 cases) were described in 2015, all involving additional prescription medications.[11] A systematic review documented 31 UK deaths involving MXP alone or in combination, with 14 attributed to MXP as the primary cause.[7] Demographics were predominantly male (91.4%), with a mean age of 37. Peak death years were 2014–2016. Eight additional deaths outside Europe were documented (4 Japan, 4 USA).[7]
Heart and circulation
Elevated blood pressure and rapid heart rate are the most consistent clinical findings, occurring in 76% and 47% of documented intoxication cases respectively.[18][12]
Street sample contamination
Analysis of street MXP has revealed zinc halide complex impurities from the synthesis process.[8] These impurities dramatically increase cell toxicity compared to laboratory-grade MXP across kidney, liver, and bladder cell lines. Standard analytical methods and common reagent tests (Mecke, Marquis, Mandelin) typically do not identify these contaminants.[8]
Organ toxicity
The ACMD review states there is currently no evidence linking MXP to the kidney, bladder, and urinary tract damage associated with chronic ketamine use.[6] This absence reflects a lack of reported cases, not systematic investigation.
Psychological Risks
Anxiety and agitation occur in approximately 65% of clinical intoxication presentations, with altered mental status including hallucinations and confusion at a similar rate.[18] Psychotic symptoms have been documented.[12] Nearly half of analytically confirmed intoxications were classified as severe.[18]
Animal studies demonstrate schizophrenia-related behavioral changes including social withdrawal, depression-like behavior, and cognitive impairment.[16] User reports describe chronic effects including long-term memory loss and limb numbness.[4] The incidence of persistent perceptual disturbances, lasting psychosis, or enduring cognitive impairment following MXP use has not been estimated.
Tolerance & Dependence
Tolerance develops with repeated MXP use. Community estimates place the tolerance half-life at approximately 5 days, with full reset at 1.5 weeks and cross-tolerance to other dissociatives.inferred These estimates derive from class-based analogy, not controlled studies.
Physical dependence is documented. One case described a 21-year-old male who developed withdrawal symptoms — abdominal pain, vomiting, and low-grade fever — after only weeks of use.[6] The first documented MXP use disorder was reported to the French Addictovigilance Network.[19]
Rodent studies confirm reinforcing properties: MXP maintains self-administration and produces conditioned place preference.[16] The reinforcement mechanism involves indirect dopamine activation via NMDA-mediated disinhibition, rather than direct dopamine reuptake blockade.[1][16]
Drug Interactions
No MXP-specific drug interaction studies have been published. All risk assessments below are based on pharmacological class and clinical co-ingestion data.
CNS depressants (alcohol, opioids, GHB, benzodiazepines): MXP alone produces altered mental status; co-administration with CNS depressants compounds sedation and respiratory risk. Several documented fatalities involved co-ingestion of other substances.[11][12]inferred
Stimulants (cocaine, amphetamines, cathinones): MXP consistently produces elevated blood pressure and rapid heart rate as standalone effects.[18][12] Combining with stimulants compounds cardiovascular strain. MXP itself displays stimulant properties at lower doses.[4]inferred
MAOIs: No data exist for the MXP–MAOI combination. While MXP has minimal direct SERT activity,[2] NMDA antagonists can modulate serotonin systems indirectly. High caution is warranted.safety citation needed
Serotonergic drugs: MXP's negligible serotonin transporter affinity substantially reduces serotonin syndrome risk relative to more promiscuous NMDA antagonists such as dxm.[2] Indirect serotonergic modulation at the circuit level cannot be fully excluded.inferred
CYP-mediated interactions: Co-administration with potent inhibitors of liver enzymes involved in MXP's metabolism could theoretically elevate MXP blood levels. No MXP-specific enzyme interaction data exist.inferred
Contraindications
No substance-specific contraindication studies exist. The following are inferred from clinical data and pharmacological class.
Pre-existing high blood pressure or heart conditions: Elevated blood pressure and rapid heart rate are the most frequent clinical findings in MXP intoxication (76% and 47% respectively).[18]inferred
Psychotic disorders or active psychosis: MXP produces hallucinations and psychotic symptoms in clinical presentations,[18][12] and schizophrenia-like behavioral changes in animal models.[16]inferred
Seizure disorders: Seizures have been reported among adverse effects in both user accounts and clinical cases.[4][12]inferred
Liver impairment: MXP is metabolized primarily through the liver. Impaired liver function could reduce clearance and increase systemic exposure.inferred
Pregnancy and breastfeeding: No reproductive toxicology data exist. Use during pregnancy is contraindicated by precautionary principle.inferred
Harm Reduction[edit]
Forms & Identification
MXP is typically encountered as a white to off-white powder or crystalline solid. The compound's three positional isomers (2-MXP, 3-MXP, 4-MXP) share similar appearance and basic analytical profiles but carry different pharmacological effects,[14] making laboratory-grade testing the only reliable method of isomer confirmation.
Street samples have been found to contain zinc halide synthesis impurities that standard reagent tests (Mecke, Marquis, Mandelin) and common analytical methods do not detect.[8] These impurities dramatically increase cellular toxicity. Sourcing from vendors with third-party analytical verification reduces — but does not eliminate — this risk.
Guidelines
- Test every batch with reagent kits and, where available, quantitative analysis — reagent tests alone cannot detect zinc halide impurities[8]
- Start at the low end of the dose range, especially with untested material or new batches
- Do not redose during the first 90 minutes — the slow onset creates a deceptive window that drives accidental overdose[5]
- Have a sober sitter present for the full duration
- Keep the environment controlled — remove access to heights, water, roads, and sharp objects before onset
- Pre-arrange a 24-hour window with no obligations — the experience is long and aftereffects can persist
- Stay hydrated but avoid alcohol
Set & Setting
MXP's extended duration and biphasic character demand planning. The experience includes unpredictable shifts between stimulant-like waves and heavy dissociative sedation,[4] making it poorly suited to environments requiring mobility, social coherence, or quick decision-making.
A sober, trusted sitter is strongly recommended, particularly at doses approaching the upper range. Prior dissociative experience and current tolerance level modulate the experience significantly.[5] A familiar, safe, comfortable environment with minimal external stimulation is optimal.
Aftercare & integration. The extended duration and cognitive disruption of MXP mean recovery requires time. Allow at least 24 hours of low-demand activity after the acute effects resolve. Sleep may be difficult in the hours following the experience — this is expected and typically resolves within a day.
Dissociative experiences can leave residual feelings of unreality or detachment that may persist for hours to days. Grounding practices — physical activity, structured routine, social contact, time outdoors — help re-establish a normal sense of embodiment. If feelings of unreality, memory difficulty, or emotional flatness persist beyond a few days, consult a healthcare provider.
Recovery & Support
Physical dependence on MXP can develop after relatively short periods of heavy use.[6] Withdrawal symptoms including abdominal pain, vomiting, and fever have been documented. Anyone experiencing difficulty controlling use or withdrawal symptoms when stopping should seek medical support.
Dissociative use disorders are recognized in addiction medicine. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential treatment referrals. For those outside the US, national addiction services or a general practitioner can provide referrals to appropriate care.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: MXP intoxication becomes a medical emergency when any of the following occur: seizure, loss of consciousness with no response to loud voice or sternal rub, difficulty breathing, chest pain, body temperature that feels extremely hot through clothing, or severe agitation with risk of self-harm.
Immediate steps:
- 1. Call emergency services immediately
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear)
- 3. Do not restrain an agitated person unless they are in immediate physical danger — restraint can escalate the situation
- 4. Monitor breathing continuously until help arrives
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (methoxphenidine / MXP), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution. No reversal agent exists for MXP — treatment is supportive.
Legal Status[edit]
Methoxphenidine occupies an evolving international regulatory position. The WHO Expert Committee on Drug Dependence reviewed MXP in October 2020, and the Commission on Narcotic Drugs decided in April 2021 not to add it to the UN Convention on Psychotropic Substances, instead placing it under continuing international surveillance.[6] Individual nations have moved ahead of international scheduling with domestic controls.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class B, Schedule 1 (Misuse of Drugs Act 1971) | Controlled since 20 March 2024 via SI 2024/190. Possession: max 5 years. Supply/production: max 14 years. Research requires Home Office licence. Previously covered by Psychoactive Substances Act 2016 from May 2016.[13] |
| Canada | Schedule I (CDSA) | Possession without authority: max 7 years imprisonment.[6] |
| Australia | Schedule 9 (Prohibited substance, SUSMP) | Effective 1 October 2024. Research use only with permit. |
| France | Narcotic drug (Annex IV) | Classified under French drug control regulations. Exact scheduling date unconfirmed.[12] |
| China | Controlled substance | Controlled from September 2015.[6] |
| Italy | Controlled substance | Controlled from August 2016.[6] |
| Sweden | Controlled substance | Controlled; date not confirmed.[6] |
| Denmark | Controlled substance | Controlled; date not confirmed.[6] |
| Japan | Designated Substance | Listed on Designated Substance list; exact date not confirmed.[6] |
| United States | Not specifically scheduled (CSA) | Not scheduled under the Controlled Substances Act as of the most recent confirmed information. Potentially covered by the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption and shown to be substantially similar to a Schedule I/II substance. No formal DEA scheduling action confirmed. safety citation needed |
references
- [1] ^abcdefSahai MA, Davidson C, Dutta N, Opacka-Juffry J (2018) Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter-In Silico and In Vitro Exploration of Dissociative Diarylethylamines — Brain Sciences doi:10.3390/brainsci8040063
- [2]
- [3]
- [4]
- [5] ^abcdHearne E, Van Hout MC (2016) "Trip-Sitting" in the Black Hole: A Netnographic Study of Dissociation and Indigenous Harm Reduction — Journal of Psychoactive Drugs doi:10.1080/02791072.2016.1207827
- [6]